Trial Profile
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Selonsertib (Primary)
- Indications Diabetic nephropathies; Non-alcoholic steatohepatitis; Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 21 Dec 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 21 Aug 2015 Status changed from not yet recruiting to recruiting ClinicalTrials.gov.
- 30 Jul 2015 New trial record